KRIBIOLISA™ Clazakizumab ELISA

SKU: KBI1235 Category:

58,000.00

Enzyme Immunoassay for the estimation of Clazakizumab in serum and plasma.

About the kit:
– Uses anti-idiotypic monoclonal antibodies which ensures higher specificity, and low cross reactivity.
– Recovery rates are between 85 – 115%
– Validated as per US FDA guidelines for Bioassays
– Precision CV<10%

Availability: 3 – 4 weeks | Pack Size: 1 x 96 wells



Description

Background:
Clazakizumab is an aglycosylated, humanized rabbit monoclonal antibody against interleukin-6. An investigational drug, it is currently being studied for the treatment of psoriatic arthritis (PsA) and renal antibody-mediated rejection. It has also been considered as a therapeutic for SARS-CoV-2 due to its high affinity to IL-6.

Intended Use:
For Estimation of Clazakizumab in human serum and plasma. Krishgen’s range of KRIBIOLISA kits are developed using the high quality raw materials and are thoroughly validated for accuracy and precison. They allow quantification of serum or plasma protein drug levels, and can be used for biosimilar and generics research to understand pharmacokinetic properties of the drug. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us for optimisation.

If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!

View more details about our Publication Reward

Additional information

Species

Human

Biomarker Estimation

measures free drug

Sample Type

Serum (100 ul), EDTA Plasma (100 ul), Heparin Plasma (100 ul), Citrate Plasma (100 ul)

Calibration Range

0 ng/ml – 2000 ng/ml

Detection Method

Colorimetric

Specificity

80% – 120% to Clazakizumab

Cross Reactivity

< 0.5% cross-reactivity observed with related biomarker.

Interference

No significant interference observed with available related molecules.

Regulatory Status

Research Use Only

Research Area

Biosimilars / Therapeutic Drug Monitoring / Fusion Proteins

Alternate Names / Synonyms

BMS-945429, Clazakizumab

Drug Bank Accession Number

DB12849

ELISA Type

Direct Sandwich Assay

Storage Temperature

Store the unopened product at 2-8?C. Do not use past expiration date.

Validation

The kit uses a biosimilar research grade standard / calibrator. The standard / calibrator has been validated against WHO/NIBSC standard and/or against commercially sourced innovator drug where available. Please refer the IFU for more details.

Disclaimer

Trade name indicated is for reference purposes only. It does not reflect any licences or patent usage. The tradename is the registered trademark of the respective owners only.

Long Name

Protein Based Therapies – Monoclonal Antibody